NCT00186628: Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD |
|
|
| Completed | 2 | 36 | US | Total lymphoid irradiation, TLI, Rituximab, Rituxan, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, CSP, Sandimmune, Mycophenylate mofetil, MMF, CellCept, Filgrastim, G-CSF, Granulocyte-colony stimulating factor, Neupogen, Granisetron, Sancuso, Solumedrol, Medrol, Depo-Medrol, A-Methapred, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Hydrocortisone, Westcort | Stanford University, The Leukemia and Lymphoma Society, National Cancer Institute (NCI) | Leukemia, Mast-Cell, Mantle-cell Lymphoma | 11/10 | 12/10 | | |
